← Back to Search

Glucagon-like peptide-1 (GLP-1) receptor agonist

Tirzepatide for Obesity (SURMOUNT-3 Trial)

Phase 3
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have a body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 and previously diagnosed with at least 1 of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease
History of at least one unsuccessful dietary effort to lose body weight
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 weeks
Awards & highlights

SURMOUNT-3 Trial Summary

This trial will study the effects of tirzepatide in obese people. It will last 29 visits and span 2 years, in order to see if tirzepatide can help with weight loss or maintenance.

Eligible Conditions
  • Obesity

SURMOUNT-3 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have a high body mass index (BMI) and have been diagnosed with conditions like high blood pressure, high cholesterol, sleep apnea, or heart disease.
Select...
You have tried to lose weight through dieting before but were not successful.

SURMOUNT-3 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change from Randomization in Body Weight
Percentage of Participants with ≥5% Body Weight Reduction
Secondary outcome measures
Change from Baseline in Absolute Body Weight
Change from Baseline in BMI
Change from Baseline in Waist Circumference
+20 more

Side effects data

From 2022 Phase 3 trial • 210 Patients • NCT05024032
40%
Diarrhoea
30%
Nausea
27%
Decreased appetite
23%
Upper respiratory tract infection
19%
Abdominal distension
11%
Gastroenteritis
11%
Vomiting
9%
Flatulence
9%
Abortion induced
7%
Amylase increased
7%
Lipase increased
7%
Abdominal pain upper
7%
Gingivitis
6%
Injection site reaction
6%
Menstruation irregular
6%
Abdominal pain
4%
Hyperuricaemia
4%
Hepatic function abnormal
3%
Vaginal infection
3%
Dizziness
3%
Uterine polyp
1%
Hiccups
1%
Supraventricular tachycardia
1%
Hand fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
10 mg Tirzepatide
15 mg Tirzepatide
Placebo

SURMOUNT-3 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TirzepatideExperimental Treatment1 Intervention
Tirzepatide administered subcutaneously (SC)
Group II: PlaceboPlacebo Group1 Intervention
Administered SC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tirzepatide
2019
Completed Phase 3
~7590

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,605 Previous Clinical Trials
3,198,864 Total Patients Enrolled
52 Trials studying Obesity
39,954 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,338 Previous Clinical Trials
403,039 Total Patients Enrolled
35 Trials studying Obesity
19,673 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA cleared Tirzepatide for public consumption?

"There is available clinical data that supports the efficacy of Tirzepatide, making it a safe medication with a score of 3."

Answered by AI

To your knowledge, has a study like this been conducted before?

"Tirzepatide has been under scientific study since 2019 when it was first developed by Eli Lilly and Company. After the initial Phase 1 study on 196 individuals, Tirzepatide received approval for Phase 2 testing. As of now, there are 10 ongoing studies involving Tirzepatide in 621 locations across 31 countries."

Answered by AI

Are there other examples of Tirzepatide's effectiveness?

"Tirzepatide was first studied in 2019 by American Research Corporation at Texas Liver Institute. Following that, there have been 18302 completed clinical trials. Right now, 10 clinical trials are actively recruiting patients with a significant portion of these studies based out of Pittsburgh, Pennsylvania."

Answered by AI

What are the benefits that researchers hope to gain from this clinical trial?

"This clinical trial will last for approximately 72 weeks and its primary goal is to track the percent change in body weight of participants. Additionally, the study hopes to understand how effective the intervention is by measuring the percentage of patients who achieve a ≥15% reduction in body weight, changes in physical function (as measured by the Short Form 36 Version 2 Health Survey), and changes in waist circumference."

Answered by AI

Are there more than one location where this research project is taking place within the state?

"44 clinical trial sites are actively recruiting patients for this study, which includes locations in Pittsburgh, Dallas and Muncie. To reduce travel burden, please select the location nearest to you when enrolling."

Answered by AI

How many test subjects are required for this experiment?

"Unfortunately, this study has already closed recruitment. However, there are presently 1191 clinical trials actively admitting patients with obesity and 10 trials for Tirzepatide actively enrolling participants."

Answered by AI

Are there still positions available for volunteers in this research project?

"Information available on clinicaltrials.gov suggests that this particular study is not presently looking for patients to enroll. Although the trial's last update was on March 22nd, 2022, it is one of 1201 other trials recruiting subjects as we speak."

Answered by AI

Who else is applying?

What state do they live in?
Florida
California
Texas
Other
How old are they?
65+
18 - 65
What site did they apply to?
National Research Institute - Wilshire
Catalina Research Institute, LLC
Diablo Clinical Research, Inc.
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
2
3+
0

Why did patients apply to this trial?

I need to lose weight. I want to improve my health. i need to make some decent money.
PatientReceived 2+ prior treatments
I’ve tried diets and nothing worked. I have tried 3 times to loose weight.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

How long would this trial be? How long to appointments usually take? Can the visits be done in South Central Missouri or North Central AR?
PatientReceived 1 prior treatment
How long are visits? Does marijuana use from 2 weeks ago disqualify me?
PatientReceived no prior treatments

How responsive is this trial?

Typically responds via
Phone Call
Most responsive sites:
  1. Cleveland Clinic Foundation: < 24 hours
  2. National Research Institute (NRI) - Santa Ana: < 48 hours
Average response time
  • < 2 Days
~201 spots leftby Mar 2025